Combined analysis of transcriptome and proteome data as a tool for the identification of candidate biomarkers in renal cell carcinoma

Proteomics

Volumn 9, Issue 6, 2009, Pages 1567-1581

  Seliger, Barbara ^a   Dressler, Sven P ^a   Wang, Ena ^b   Kellner, Roland ^c   Recktenwald, Christian V ^a   Lottspeich, Friedrich ^d   Marincola, Francesco M ^b   Baumgärtner, Maja ^a   Atkins, Derek ^e   Lichtenfels, Rudolf ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c MERCK KGAA   (Germany)

^d MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^e UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

Biomarkers; Proteome based technologies; RCC; Transcriptomics

Indexed keywords

ACTIN; ALDEHYDE REDUCTASE; ALPHA CRYSTALLIN; ALPHA ENOLASE; ALPHA TUBULIN; BIOLOGICAL MARKER; CARRIER PROTEIN; COLLAGEN TYPE 2; COMPLEMENTARY DNA; GLUCOSE REGULATED PROTEIN 78; GLUTATHIONE SYNTHASE; GLUTATHIONE TRANSFERASE ALPHA; GLUTATHIONE TRANSFERASE P1; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HEAT SHOCK PROTEIN 60; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; KERATIN TYPE II; LIPOCORTIN 2; LIPOCORTIN 4; LIPOCORTIN 5; MOESIN; NICOTINAMIDE METHYLTRANSFERASE; PROTEIN DISULFIDE ISOMERASE; THIOREDOXIN; TRIOSEPHOSPHATE ISOMERASE; TROPOMYOSIN; UBIQUITIN THIOLESTERASE; UNINDEXED DRUG; VIMENTIN;

AMINO ACID SEQUENCE; ARTICLE; CANCER DIAGNOSIS; CELL METABOLISM; CELL MOTILITY; CELL STRUCTURE; DNA MICROARRAY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; SIGNAL TRANSDUCTION; TRANSCRIPTOMICS; UNINDEXED SEQUENCE; UPREGULATION;

AGED; CARCINOMA, RENAL CELL; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; EPITHELIUM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROTEOME; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL;

EID: 63049132403     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.200700288     Document Type: Article

References (58)

1. Ding, C., Cantor, C. R., Quantitative analysis of nucleic acids - The last few years of progress. J. Biochem. Mol. Biol. 2004, 37, 1-10.
2. Guo, Q. M., DNA microarray and cancer. Curr. Opin. Oncol. 2003, 15, 36-43.
3. Waters, K. M., Pounds, J. G., Thrall, B. D., Data merging for integrated microarray and proteomic analysis. Brief. Funct. Genomic Proteomic 2006, 5, 261-272.
4. Tian, Q., Stepaniants, S. B., Mao, M., Weng, L. et al., Integrated genomic and proteomic analyses of gene expression in Mammalian cells. Mol. Cell. Proteomics 2004, 3, 960-969.
5. Brockmann, R., Beyer, A., Heinisch, J. J., Wilhelm, T., Posttranscriptional expression regulation: What determines translation rates? PLoS Comput. Biol. 2007, 3, e57.
6. Ideker, T., Thorsson, V., Ranish, J. A., Christmas, R. et al., Integrated genomic and proteomic analyses of a systematically perturbed metabolic network. Science 2001, 292, 929-934.
7. Graham, D. R., Garnham, C. P., Fu, Q., Robbins, J., Van Eyk, J. E., Improvements in two-dimensional gel electrophoresis by utilizing a low cost "in-house" neutral pH sodium dodecyl sulfate-polyacrylamide gel electrophoresis system. Proteomics 2005, 5, 2309-2314.
8. Miles, A. K., Matharoo-Ball, B., Li, G., Ahmad, M., Rees, R. C., The identification of human tumour antigens: Current status and future developments. Cancer Immunol. Immunother. 2006, 55, 996-1003.
9. Merrick, B. A., Bruno, M. E., Genomic and proteomic profiling for biomarkers and signature profiles of toxicity. Curr. Opin. Mol. Ther. 2004, 6, 600-607.
10. Hu, Y. F., Kaplow, J., He, Y., From traditional biomarkers to transcriptome analysis in drug development. Curr. Mol. Med. 2005, 5, 29-38.
11. Seliger, B., Lichtenfels, R., Kellner, R., Detection of renal cell carcinoma-associated markers via proteome- and other 'ome'-based analyses. Brief. Funct. Genomic Proteomic 2003, 2, 194-212.
12. Mostofi, F. K., Davies, C. J., Jr., Sobin, L. H., Histological Typing of Kidney Tumors. Springer, Berlin 1998.
13. Gouttefangeas, C., Stenzl, A., Stevanovic, S., Rammensee, H. G., Immunotherapy of renal cell carcinoma. Cancer Immunol. Immunother. 2007, 56, 117-128.
14. Ahmad, T., Eisen, T., Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin. Cancer Res. 2004, 10, 6388S-6392S.
15. Marx, J., Cancer. Encouraging results for second-generation antiangiogenesis drugs. Science 2005, 308, 1248-1249.
16. Wang, E., Lichtenfels, R., Bukur, J., Ngalame, Y. et al., Ontogeny and oncogenesis balance the transcriptional profile of renal cell cancer. Cancer Res. 2004, 64, 7279-7287.
17. Scherer, A., Krause, A., Walker, J. R., Sutton, S. E. et al., Optimized protocol for linear RNA amplification and application to gene expression profiling of human renal biopsies. Biotechniques 2003, 34, 546-550, 552-544, 556.
18. Shi, T., Dong, F., Liou, L. S., Duan, Z. H. et al., Differential protein profiling in renal-cell carcinoma. Mol. Carcinog. 2004, 40, 47-61.
19. Kellner, R., Lichtenfels, R., Atkins, D., Bukur, J. et al., Targeting of tumor associated antigens in renal cell carcinoma using proteome-based analysis and their clinical significance. Proteomics 2002, 2, 1743-1751.
20. Seliger, B., Menig, M., Lichtenfels, R., Atkins, D. et al., Identification of markers for the selection of patients undergoing renal cell carcinoma-specific immunotherapy. Proteomics 2003, 3, 979-990.
21. Lichtenfels, R., Kellner, R., Bukur, J., Beck, J. et al., Heat shock protein expression and anti-heat shock protein reactivity in renal cell carcinoma. Proteomics 2002, 2, 561-570.
22. Lichtenfels, R., Kellner, R., Atkins, D., Bukur, J. et al., Identification of metabolic enzymes in renal cell carcinoma utilizing PROTEOMEX analyses. Biochim. Biophys. Acta 2003, 1646, 21-31.
23. Seliger, B., Lichtenfels, R., Atkins, D., Bukur, J. et al., Identification of fatty acid binding proteins as markers associated with the initiation and/or progression of renal cell carcinoma. Proteomics 2005, 5, 2631-2640.
24. Craven, R. A., Stanley, A. J., Hanrahan, S., Dods, J. et al., Proteomic analysis of primary cell lines identifies protein changes present in renal cell carcinoma. Proteomics 2006, 6, 2853-2864.
25. Perego, R. A., Bianchi, C., Corizzato, M., Eroini, B. et al., Primary cell cultures arising from normal kidney and renal cell carcinoma retain the proteomic profile of corresponding tissues. J. Proteome Res. 2005, 4, 1503-1510.
26. Banks, R. E., Craven, R. A., Harnden, P., Madaan, S. et al., Key clinical issues in renal cancer: A challenge for proteomics. World J. Urol. 2007, 25, 537-556.
27. Kim, H. L., Seligson, D., Liu, X., Janzen, N. et al., Using protein expressions to predict survival in clear cell renal carcinoma. Clin. Cancer Res. 2004, 10, 5464-5471.
28. Seliger, B., Hohne, A., Knuth, A., Bernhard, H. et al., Analysis of the major histocompatibility complex class I antigen presentation machinery in normal and malignant renal cells: Evidence for deficiencies associated with transformation and progression. Cancer Res. 1996, 56, 1756-1760.
29. Lichtenfels, R., Ackermann, A., Kellner, R., Seliger, B., Mapping and expression pattern analysis of key components of the major histocompatibility complex class I antigen processing and presentation pathway in a representative human renal cell carcinoma cell line. Electrophoresis 2001, 22, 1801-1809.
30. Seliger, B., Fedorushchenko, A., Brenner, W., Ackermann, A. et al., Ubiquitin COOH-terminal hydrolase 1: A biomarker of renal cell carcinoma associated with enhanced tumor cell proliferation and migration. Clin. Cancer Res. 2007, 13, 27-37.
31. Wang, E., Miller, L. D., Ohnmacht, G. A., Liu, E. T., Marincola, F. M., High-fidelity mRNA amplification for gene profiling. Nat. Biotechnol. 2000, 18, 457-459.
32. Recktenwald, C. V., Mendler, S., Lichtenfels, R., Kellner, R., Seliger, B., Influence of Ki-ras-driven oncogenic transformation on the protein network of murine fibroblasts. Proteomics 2007, 7, 385-398.
33. Atkins, D., Ferrone, S., Schmahl, G. E., Storkel, S., Seliger, B., Down-regulation of HLA class I antigen processing molecules: An immune escape mechanism of renal cell carcinoma? J. Urol. 2004, 171, 885-889.
34. Atkins, D., Lichtenfels, R., Seliger, B., Heat shock proteins in renal cell carcinomas. Contrib. Nephrol. 2005, 148, 35-56.
35. Young, A. N., Amin, M. B., Moreno, C. S., Lim, S. D. et al., Expression profiling of renal epithelial neoplasms: A method for tumor classification and discovery of diagnostic molecular markers. Am. J. Pathol. 2001, 158, 1639-1651.
36. Unwin, R. D., Craven, R. A., Harnden, P., Hanrahan, S. et al., Proteomic changes in renal cancer and co-ordinate demonstration of both the glycolytic and mitochondrial aspects of the Warburg effect. Proteomics 2003, 3, 1620-1632.
37. Balabanov, S., Zimmermann, U., Protzel, C., Scharf, C. et al., Tumour-related enzyme alterations in the clear cell type of human renal cell carcinoma identified by two-dimensional gel electrophoresis. Eur. J. Biochem. 2001, 268, 5977-5980.
38. Pancholi, V., Multifunctional alpha-enolase: Its role in diseases. Cell. Mol. Life Sci. 2001, 58, 902-920.
39. Yoneda, M., Fujii, A., Ito, A., Yokoyama, H. et al., High prevalence of serum autoantibodies against the amino terminal of alpha-enolase in Hashimoto's encephalopathy. J. Neuroimmunol. 2007, 185, 195-200.
40. Yavlovich, A., Rechnitzer, H., Rottem, S., Alpha-enolase resides on the cell surface of Mycoplasma fermentans and binds plasminogen. Infect. Immun. 2007, 75, 5716-5719.
41. Magrys, A., Anekonda, T., Ren, G., Adamus, G., The role of anti-alpha-enolase autoantibodies in pathogenicity of autoimmune-mediated retinopathy. J. Clin. Immunol. 2007, 27, 181-192.
42. He, P., Naka, T., Serada, S., Fujimoto, M. et al., Proteomics-based identification of alpha-enolase as a tumor antigen in nonsmall lung cancer. Cancer Sci. 2007, 98, 1234-1240.
43. Mori-Iwamoto, S., Kuramitsu, Y., Ryozawa, S., Mikuria, K. et al., Proteomics finding heat shock protein 27 as a biomarker for resistance of pancreatic cancer cells to gemcitabine. Int. J. Oncol. 2007, 31, 1345-1350.
44. Gerke, V., Creutz, C. E., Moss, S. E., Annexins: Linking Ca2+ signalling to membrane dynamics. Nat. Rev. Mol. Cell Biol. 2005, 6, 449-461.
45. Park, J. E., Lee, D. H., Lee, J. A., Park, S. G. et al., Annexin A3 is a potential angiogenic mediator. Biochem. Biophys. Res. Commun. 2005, 337, 1283-1287.
46. Wozny, W., Schroer, K., Schwall, G. P., Poznanovic, S. et al., Differential radioactive quantification of protein abundance ratios between benign and malignant prostate tissues: Cancer association of annexin A3. Proteomics 2007, 7, 313-322.
47. Kollermann, J., Schlomm, T., Bang, H., Schwall, G. P. et al., Expression and prognostic relevance of annexin A3 in prostate cancer. Eur. Urol. 2008, 54, 1314-1323.
48. Zimmermann, U., Balabanov, S., Giebel, J., Teller, S. et al., Increased expression and altered location of annexin IV in renal clear cell carcinoma: A possible role in tumour dissemination. Cancer Lett. 2004, 209, 111-118.
49. Chen, G., Gharib, T. G., Huang, C. C., Taylor, J. M. et al., Discordant protein and mRNA expression in lung adenocarcinomas. Mol. Cell. Proteomics 2002, 1, 304-313.
50. Corthals, G. L., Wasinger, V. C., Hochstrasser, D. F., Sanchez, J. C., The dynamic range of protein expression: A challenge for proteomic research. Electrophoresis 2000, 21, 1104-1115.
51. Rabilloud, T., Two-dimensional gel electrophoresis in proteomics: Old, old fashioned, but it still climbs up the mountains. Proteomics 2002, 2, 3-10.
52. Shi, T., Seligson, D., Belldegrun, A. S., Palotie, A., Horvath, S., Tumor classification by tissue microarray profiling: Random forest clustering applied to renal cell carcinoma. Mod. Pathol. 2005, 18, 547-557.
53. Lian, Z., Kluger, Y., Greenbaum, D. S., Tuck, D. et al., Genomic and proteomic analysis of the myeloid differentiation program: Global analysis of gene expression during induced differentiation in the MPRO cell line. Blood 2002, 100, 3209-3220.
54. Gygi, S. P., Han, D. K., Gingras, A. C., Sonenberg, N., Aebersold, R., Protein analysis by mass spectrometry and sequence database searching: Tools for cancer research in the post-genomic era. Electrophoresis 1999, 20, 310-319.
55. Abdulrahman, M., Maina, E. N., Morris, M. R., Zatyka, M. et al., Identification of novel VHL targets that are associated with the development of renal cell carcinoma. Oncogene 2007, 26, 1661-1672.
56. Wykoff, C. C., Pugh, C. W., Maxwell, P. H., Harris, A. L., Ratcliffe, P. J., Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling. Oncogene 2000, 19, 6297-6305.
57. Dallmann, K., Junker, H., Balabanov, S., Zimmermann, U. et al., Human agmatinase is diminished in the clear cell type of renal cell carcinoma. Int. J. Cancer 2004, 108, 342-347.
58. Alchanati, I., Nallar, S. C., Sun, P., Gao, L. et al., A proteomic analysis reveals the loss of expression of the cell death regulatory gene GRIM-19 in human renal cell carcinomas. Oncogene 2006, 25, 7138-7147.